Given the lack of efficacy of AKT inhibitors in melanoma, we used our established mouse models to further elucidate the molecular mechanisms by which AKT1 contributes to metastatic spread in an effort to identify alternative therapeutic targets. This evidence concerns the gene AKT1 and melanoma.